{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:43:30Z","timestamp":1781790210228,"version":"3.54.5"},"reference-count":118,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The hepatitis B virus is responsible for most of the chronic liver disease and liver cancer worldwide. As actual therapeutic strategies have had little success in eradicating the virus from hepatocytes, and as lifelong treatment is often required, new drugs targeting the various phases of the hepatitis B virus (HBV) lifecycle are currently under investigation. In this review, we provide an overview of potential future treatments for HBV.<\/jats:p>","DOI":"10.3390\/v13091767","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T23:55:22Z","timestamp":1630972522000},"page":"1767","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatments for HBV: A Glimpse into the Future"],"prefix":"10.3390","volume":"13","author":[{"given":"Alessandra","family":"Bartoli","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Internal Medicine, Maternal-Infantile and Adult, University of Modena and Reggio Emilia, 41126 Modena, Italy"},{"name":"Postgraduate School of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Internal Medicine, Maternal-Infantile and Adult, University of Modena and Reggio Emilia, 41126 Modena, Italy"},{"name":"Postgraduate School of Internal Medicine, University of Modena and Reggio Emilia, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tassi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Internal Medicine, Maternal-Infantile and Adult, University of Modena and Reggio Emilia, 41126 Modena, Italy"},{"name":"Postgraduate School of Internal Medicine, University of Modena and Reggio Emilia, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Cursaro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Internal Medicine, Maternal-Infantile and Adult, University of Modena and Reggio Emilia, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Pinelli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Internal Medicine, Maternal-Infantile and Adult, University of Modena and Reggio Emilia, 41126 Modena, Italy"},{"name":"Postgraduate School of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-9809","authenticated-orcid":false,"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Internal Medicine, Maternal-Infantile and Adult, University of Modena and Reggio Emilia, 41126 Modena, Italy"},{"name":"Postgraduate School of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"key":"ref_1","unstructured":"(2021, March 30). WHO|Global Hepatitis Report. Available online: http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13291","article-title":"Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)","volume":"37","author":"Grossi","year":"2017","journal-title":"Liver Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0021-9258(17)49936-4","article-title":"The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network","volume":"295","author":"Iwamoto","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.1811064116","article-title":"Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization","volume":"116","author":"Iwamoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1128\/JVI.02303-05","article-title":"Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events","volume":"80","author":"Rabe","year":"2006","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1073\/pnas.1730940100","article-title":"Nuclear import of hepatitis B virus capsids and release of the viral genome","volume":"100","author":"Rabe","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Long, Q., Yan, R., Hu, J., Cai, D., Mitra, B., Kim, E.S., Marchetti, A., Zhang, H., Wang, S., and Liu, Y. (2017). The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006784"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Qi, Y., Gao, Z., Peng, B., Liu, C., Yan, H., Yao, Q., Sun, G., Liu, Y., Tang, D., and Song, Z. (2016). DNA Polymerase \u03ba Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005893"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tang, L., Sheraz, M., McGrane, M., Chang, J., and Guo, J.T. (2019). DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007742"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e02230-18","DOI":"10.1128\/JVI.02230-18","article-title":"Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA","volume":"93","author":"Sheraz","year":"2019","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e01032-19","DOI":"10.1128\/JVI.01032-19","article-title":"Revisiting Hepatitis B Virus: Challenges of Curative Therapies","volume":"93","author":"Hu","year":"2019","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","article-title":"Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis","volume":"75","author":"Zhu","year":"2001","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104925","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/386088a0","article-title":"Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy","volume":"386","author":"Wynne","year":"1997","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/386091a0","article-title":"Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy","volume":"386","author":"Conway","year":"1997","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_23","unstructured":"Czarsk, A., and Thorley, D. (2021, April 07). Hepcludex [Internet]. European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex."},{"key":"ref_24","first-page":"2049936120965027","article-title":"Advances in hepatitis B therapeutics","volume":"7","author":"Soriano","year":"2020","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"van den Berg, F., Limani, S.W., Mnyandu, N., Maepa, M.B., Ely, A., and Arbuthnot, P. (2020). Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses, 12.","DOI":"10.3390\/v12080851"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cld.2019.04.006","article-title":"Drugs in the Pipeline for HBV","volume":"23","author":"Lopatin","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1021\/jm049481d","article-title":"Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asialoglycoprotein Receptor","volume":"47","author":"Rensen","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_30","unstructured":"Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., and Liang, X.J. (2021, April 12). Therapeutic siRNA: State of the Art, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7305320\/."},{"key":"ref_31","unstructured":"(2021, April 12). Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4. Available online: https:\/\/investor.arbutusbio.com\/news-releases\/news-release-details\/arbutus-announces-topline-results-arb-1467-phase-ii-cohort-4."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","article-title":"The Crystal Structure of the Human Hepatitis B Virus Capsid","volume":"3","author":"Wynne","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Guo, F., Zhao, Q., Sheraz, M., Cheng, J., Qi, Y., Su, Q., Cuconati, A., Wei, L., Du, Y., and Li, W. (2017). HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathogens., 13.","DOI":"10.1371\/journal.ppat.1006658"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.antiviral.2017.11.015","article-title":"The diverse functions of the hepatitis B core\/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals","volume":"149","author":"Diab","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hep.30514","article-title":"Direct Inhibition of Hepatitis B e Antigen by Core Protein Allosteric Modulator","volume":"70","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_38","unstructured":"(2021, April 08). RO7049389, a Core Protein Allosteric Modulator, Demonstrates Robust Decline in HBV DNA and HBV RNA in Chronic HBV Infected Patients. Available online: https:\/\/www.natap.org\/2019\/EASL\/EASL_125.htm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: A randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection","volume":"73","author":"Zhang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","unstructured":"(2021, April 29). Antiviral Activity, Pharmacokinetics, and Safety of the Second-Generation Hepatitis B Core Inhibitor ABI-H2158 in a Phase 1b Study of Patients with HBeAg Positive Chronic Hepatitis B Infection. Available online: https:\/\/www.natap.org\/2020\/EASL\/EASL_114.htm."},{"key":"ref_42","unstructured":"(2021, April 08). JNJ-64530440 (JNJ-0440), A Novel, Class N Capsid Assembly Modulator (CAM-N): Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Ascending Doses in Patients with Chronic Hepatitis B. Available online: https:\/\/www.natap.org\/2019\/AASLD\/AASLD_30.htm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/liv.14364","article-title":"Can we cure hepatitis B virus with novel direct-acting antivirals?","volume":"40","author":"Martinez","year":"2020","journal-title":"Liver Int."},{"key":"ref_44","unstructured":"Tanwandee, T. (2017, January 20). Oral Presentation at EASL Highlights ContraVir\u2019s Tenofovir Exalidex (TXL\u2122) Antiviral Activity in Hepatitis B (HBV) Patients. Proceedings of the International Liver Congress\u2122, EASL 2017\u2014European Association for the Study of the Liver, Amsterdam, The Netherlands."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ma, Z., Cao, Q., Xiong, Y., Zhang, E., and Lu, M. (2018). Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. Vaccines, 6.","DOI":"10.3390\/vaccines6010006"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3389\/fimmu.2019.03127","article-title":"Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection","volume":"10","author":"Meng","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41423-019-0255-8","article-title":"Activation of the TLR signaling pathway in CD8+ T cells counteracts liver endothelial cell-induced T cell tolerance","volume":"16","author":"Zhang","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","article-title":"Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism","volume":"68","author":"Niu","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.12_12922","article-title":"Combination treatment of a TLR7 agonist RO7020531 and a capsid assembly modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model","volume":"25","author":"Lue","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jvh.12942","article-title":"Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment","volume":"25","author":"Agarwal","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ezzikouri, S., Kayesh, M.E.H., Benjelloun, S., Kohara, M., and Tsukiyama-Kohara, K. (2020). Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines, 8.","DOI":"10.3390\/vaccines8020216"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S693","DOI":"10.1016\/S0168-8278(17)31861-5","article-title":"Antiviral efficacy of a novel hepatitis B virus expression inhibitor in combination with entecavir and wIFN-alpha in woodchucks model of chronic hepatitis B","volume":"66","author":"Wildum","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_55","unstructured":"(2021, April 09). Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Available online: https:\/\/www.natap.org\/2019\/AASLD\/AASLD_79.htm."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Alexopoulou, A., Vasilieva, L., and Karayiannis, P. (2020). New Approaches to the Treatment of Chronic Hepatitis B. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103187"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Suresh, M., Korolowicz, K.E., Balarezo, M., Iyer, R.P., Padmanabhan, S., Cleary, D., Gimi, R., Sheri, A., Yon, C., and Kallakury, B.V. (2017). Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169631"},{"key":"ref_58","unstructured":"Yuen, M.F., Chen, C.Y., Liu, C.J., Jeng, R.W.J., Elkhashab, M., Coffin, C., Kim, W., Greenbloom, S., Ramji, A., and Lim, Y.S. (2021, April 09). Ascending Dose Cohort Study of Inarigivir\u2014A Novel RIG I Agonist in Chronic HBV Patients: Final Results of the ACHIEVE trial|Cochrane Library. Available online: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01943470\/full."},{"key":"ref_59","unstructured":"(2021, June 16). Spring Bank Halts Development of Inarigivir for Hepatitis B. Available online: https:\/\/www.clinicaltrialsarena.com\/news\/spring-bank-stops-inarigivir-hbv\/."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/febs.13563","article-title":"The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly","volume":"283","author":"Dansako","year":"2016","journal-title":"FEBS J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14281","DOI":"10.1038\/s41598-019-50656-5","article-title":"Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice","volume":"9","author":"Martin","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12351","DOI":"10.1038\/s41598-018-30956-y","article-title":"Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/14712598.2018.1451511","article-title":"Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: A prospective multicenter randomized open-label study","volume":"18","author":"Wu","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_65","first-page":"453","article-title":"PD-1\/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection","volume":"17","author":"Watanabe","year":"2010","journal-title":"J. Viral Hepat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jhep.2019.02.016","article-title":"OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection","volume":"70","author":"Jacobi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., M\u00f6ller, I., Seiz, P., Glebe, D., and Wang, B. (2014). Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003856"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhepr.2019.06.001","article-title":"HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection","volume":"1","author":"Huang","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Boni, C., Barili, V., Acerbi, G., Rossi, M., Vecchi, A., Laccabue, D., Penna, A., Missale, G., Ferrari, C., and Fisicaro, P. (2019). HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112754"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1053\/j.gastro.2018.03.021","article-title":"Dysregulated Response of Follicular Helper T Cells to Hepatitis B Surface Antigen Promotes HBV Persistence in Mice and Associates With Outcomes of Patients","volume":"154","author":"Wang","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-014-0033-1","article-title":"Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: A multicenter, retrospective case series","volume":"2","author":"Ravi","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.4049\/jimmunol.1203449","article-title":"IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier","volume":"191","author":"Zeng","year":"2013","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/hep.29239","article-title":"Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice","volume":"66","author":"Bian","year":"2017","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.vaccine.2012.12.074","article-title":"A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice","volume":"31","author":"Buchmann","year":"2013","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1080\/21645515.2017.1319021","article-title":"Antibody-mediated immunotherapy against chronic hepatitis B virus infection","volume":"13","author":"Gao","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1016\/j.vaccine.2018.05.061","article-title":"The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens","volume":"36","author":"Chuai","year":"2018","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: A phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1016\/S0618-8278(19)30944-2","article-title":"FRI-199-First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis","volume":"70","author":"Addy","year":"2019","journal-title":"J. Hepat."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","article-title":"Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer","volume":"25","author":"Lau","year":"1997","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jhep.2008.08.026","article-title":"Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft","volume":"50","author":"Loggi","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2013-04-495531","article-title":"Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes","volume":"122","author":"Hanada","year":"2013","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/COH.0000000000000623","article-title":"Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus","volume":"15","author":"Maepa","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Bloom, K., Maepa, M.B., Ely, A., and Arbuthnot, P. (2018). Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?. Genes, 9.","DOI":"10.3390\/genes9040207"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/mt.2013.212","article-title":"An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases","volume":"22","author":"Chen","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bbrc.2016.08.152","article-title":"Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus","volume":"478","author":"Dreyer","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"26077","DOI":"10.3390\/ijms161125950","article-title":"Application of CRISPR\/Cas9 Technology to HBV","volume":"16","author":"Lin","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete Spectrum of CRISPR\/Cas9-induced Mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.addr.2020.05.010","article-title":"In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection","volume":"168","author":"Ely","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nbt.3513","article-title":"Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease","volume":"34","author":"Reik","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.29133","article-title":"PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, C., Zhang, Y., Zhu, H., Kang, Y., Liu, H., Wang, J., Qin, Y., Mao, R., and Xie, Y. (2013). Comparative analysis of CpG islands among HBV genotypes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056711"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nmeth.3733","article-title":"Editing the epigenome: Technologies for programmable transcription and epigenetic modulation","volume":"13","author":"Thakore","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_105","first-page":"111","article-title":"Hepatitis B virus can be inhibited by DNA methyltransferase 3a via specific zinc-finger-induced methylation of the X promoter","volume":"79","author":"Xirong","year":"2014","journal-title":"Biochemistry"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Bloom, K., Kaldine, H., Cathomen, T., Mussolino, C., Ely, A., and Arbuthnot, P. (2019). Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4436-y"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17460441.2017.1255195","article-title":"The current status and future directions of hepatitis B antiviral drug discovery","volume":"12","author":"Tang","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/epi.6.6.15815","article-title":"HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state","volume":"6","author":"Guo","year":"2011","journal-title":"Epigenetics"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Mueller","year":"2016","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1128\/JVI.78.18.10111-10121.2004","article-title":"Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo","volume":"78","author":"Fiedler","year":"2004","journal-title":"J. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Morrish, E., Mackiewicz, L., Silke, N., Pellegrini, M., Silke, J., Brumatti, G., and Ebert, G. (2020). Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo. Viruses, 12.","DOI":"10.3390\/v12080901"},{"key":"ref_112","unstructured":"Bonilla, J.V., and Srivatsa, S.G. (2011). Purity analysis and impurities determination by reversed-phase chromatography. Handbook of Analysis of Oligonucleotides and Related Products, Taylor & Francis Group. [1st ed.]."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Noordeen, F., Scougall, C.A., Grosse, A., Qiao, Q., Ajilian, B.B., Reaiche-Miller, G., Finnie, J., Werner, M., Broering, R., and Schlaak, J.F. (2015). Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140909"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): A non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Al-Mahtab, M., and Vaillant, A. (2016). Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156667"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bpg.2017.04.007","article-title":"Treatment of hepatitis B virus with combination therapy now and in the future","volume":"31","author":"Emery","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response","volume":"35","author":"Ferrari","year":"2015","journal-title":"Liver Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur. J. Cancer"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/9\/1767\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:56:26Z","timestamp":1760165786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/9\/1767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":118,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["v13091767"],"URL":"https:\/\/doi.org\/10.3390\/v13091767","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]}}}